ForSight Labs is a company.
ForSight Labs has raised $16.0M across 3 funding rounds.
Key people at ForSight Labs.
ForSight Labs has raised $16.0M in total across 3 funding rounds.
ForSight Labs is an ophthalmic incubator and community that creates and funds eye‑care companies developing medical devices, drug‑delivery systems, and therapies to improve vision and quality of life for visually impaired patients[1][2]. [1]
High‑Level Overview
ForSight Labs’ mission is to advance ophthalmic innovation by incubating and commercializing high‑impact eye‑care companies that improve sight, care, and quality of life for patients with ocular disease[1][7]. [1] Their investment/creation model focuses on spinning out specialized companies (separate portfolio operating entities) rather than acting as a traditional VC fund alone, partnering with venture investors and industry operators to bring technologies from concept to exit[2][5]. [2] Key sectors are ophthalmic medical devices, drug‑delivery and sustained‑release therapies for anterior and posterior segment eye disease, and related biotechnology and healthcare technologies[2][3]. [2] ForSight’s impact on the startup ecosystem is concentrated: it has repeatedly launched spin‑out companies (e.g., Transcend Medical, ForSight VISION series companies) that attracted venture capital, strategic partnerships, and at least one acquisition, creating follow‑on exits and technologies adopted by the ophthalmology market[7][5]. [7]
Origin Story
ForSight Labs was founded in 2005 as an ophthalmic incubator led by retinal surgeon Eugene de Juan Jr. in collaboration with The Foundry and experienced device investors and operators in Menlo Park, California[1][7]. [1] Early key partners and backers included Morgenthaler Ventures and Versant Ventures, which provided capital and industry expertise to form and scale spin‑outs[5][2]. [5] The incubator model produced sequential companies—Transcend Medical was an early spin‑out and ForSight Newco II (a punctal plug drug‑delivery company) was acquired by QLT—demonstrating early traction and validating the model for creating focused ophthalmic companies[7][5]. [7]
Core Differentiators
Role in the Broader Tech Landscape
ForSight Labs rides the longer‑term trend toward specialized, domain‑focused incubators that pair clinical expertise with venture and operator support to de‑risk hard‑tech/medical device development[7][5]. [7] The timing matters because ophthalmology is experiencing renewed interest in sustained‑release drug delivery, minimally invasive surgical devices, and combination device‑drug approaches—areas where focused teams and clinical validation are crucial[3][2]. [3] Market forces in favor include an aging population with rising prevalence of glaucoma, dry eye, and retinal disease, plus growing VC and strategic interest in targeted medtech solutions with clearer regulatory and reimbursement pathways compared with broad biotech discovery[2][3]. [2] By cycling technologies into standalone companies that attract venture capital and acquirers, ForSight influences the ecosystem by supplying deal flow, clinical‑grade IP, and management teams experienced in ophthalmic commercialization[7][5]. [7]
Quick Take & Future Outlook
Expect ForSight to continue spinning out specialized ophthalmic companies that target specific unmet needs (e.g., sustained topical replacement, surgical robotics or implants), leveraging clinical founders and existing VC relationships to secure Series A/B financings[2][3]. [2] Trends that will shape their journey include advances in sustained‑release drug delivery, miniaturized surgical robotics, gene and cell therapies for retinal disease, and payer emphasis on real‑world outcomes—each increasing the value of clinically validated, focused startups[3][2]. [3] If ForSight sustains its model of founder‑led spin‑outs plus strategic investor partnerships, its influence will grow as a steady source of investable ophthalmic companies and translational IP for larger device and pharma acquirers[7][5]. [7]
If you’d like, I can:
Key people at ForSight Labs.
ForSight Labs has raised $16.0M in total across 3 funding rounds.
ForSight Labs's investors include Morgenthaler Ventures.
ForSight Labs has raised $16.0M across 3 funding rounds. Most recently, it raised $9.0M Series B in June 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2013 | $9.0M Series B | Morgenthaler Ventures | |
| Apr 1, 2007 | $5.0M Series A | Morgenthaler Ventures | |
| Jan 1, 2006 | $2.0M Venture Round | Morgenthaler Ventures |
